Citigroup
IRD

Citigroup’s Opus Genetics IRD Stock Holding History

Citigroup’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Buy
+30,092
New +$140K ﹤0.01% 4565
2026
Q1 		– Sell
-496
Closed -$997 – 6499
2025
Q4 		$997 Buy
496
+495
+49,500% +$1K ﹤0.01% 5545
2025
Q3 		$2 Buy
+1
New +$1 ﹤0.01% 6032
2022
Q2 		– Sell
-66
Closed – – 6747
2022
Q1 		$0 Buy
+66
New +$226 ﹤0.01% 6659
2016
Q1 		– Hold
0
– – – 7811
2015
Q4 		– Sell
-8
Closed -$1.7K – 7911
2015
Q3 		$2K Sell
8
-7
-47% -$1.9K ﹤0.01% 7060
2015
Q2 		$4K Hold
15
– – ﹤0.01% 6903
2015
Q1 		$5K Hold
15
– – ﹤0.01% 6728
2014
Q4 		$5K Hold
15
– – ﹤0.01% 6684
2014
Q3 		$6K Sell
15
-12
-44% -$4.32K ﹤0.01% 6507
2014
Q2 		$11K Sell
27
-4
-13% -$1.82K ﹤0.01% 6137
2014
Q1 		$16K Buy
31
+10
+48% +$5.41K ﹤0.01% 6146
2013
Q4 		$6K Buy
21
+6
+40% +$1.27K ﹤0.01% 6583
2013
Q3 		$3K Hold
15
– – ﹤0.01% 6541
2013
Q2 		$3K Buy
+15
New +$2.57K ﹤0.01% 6467

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citigroup's IRD Position: Q2 2026 in Review

Citigroup opened a new position in Opus Genetics (IRD) in Q2 2026: 30,092 shares worth $124K. The stake represents ﹤0.01% of the portfolio and ranks #4565 among its holdings. This is a return to the name: Citigroup previously reported a position in IRD as recently as Q4 2025.

Citigroup first reported a position in IRD in Q2 2013 and has held it in 14 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Citigroup held 30,092 shares of Opus Genetics worth $124K as of Q2 2026.
  • Opus Genetics was a new Citigroup position in Q2 2026.
  • Opus Genetics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4565 holding.
  • Citigroup first reported a position in Opus Genetics in Q2 2013 and has held it in 14 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.